Download PDF
Semin Neurol 2018; 38(03): 278-289
DOI: 10.1055/s-0038-1660856
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Autoimmune and Paraneoplastic Myelopathies

Nicholas L. Zalewski
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
,
Eoin P. Flanagan
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
2   Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
› Author Affiliations
Further Information

Publication History

Publication Date:
16 July 2018 (online)

    Permissions and Reprints

Abstract

Prompt recognition of an inflammatory myelopathy is critical, as a specific diagnosis and management plan allows for optimal patient outcomes. Many treatment options are now available for autoimmune and paraneoplastic myelopathies, but specific management strategies and expected prognosis vary widely depending on the underlying etiology. An understanding of the relevant clinical details, imaging findings, and other diagnostic information that can help achieve a specific myelopathy diagnosis and treatment plan is essential for all neurologists, given the variety of contexts in which myelopathies are encountered. We provide an outline of the diagnostic evaluation and treatment of various inflammatory myelopathies seen in autoimmune and paraneoplastic diseases, including multiple sclerosis, aquaporin-4 immunoglobulin G (IgG) seropositive neuromyelitis optica spectrum disorder, sarcoidosis, myelin oligodendrocyte glycoprotein IgG associated disease, and other rare inflammatory myelopathies; we also highlight common mimickers of inflammatory myelopathies.

Keywords

transverse myelitis - spinal cord - neuromyelitis optica
 

  • References

  • 1 Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59 (04) 499-505
    CrossrefPubMedGoogle Scholar
  • 2 Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology 2018; 90 (02) e96-e102
    CrossrefPubMedGoogle Scholar
  • 3 McArdle MJ. McArdle's sign in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51 (08) 1110
    PubMedGoogle Scholar
  • 4 Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47 (06) 707-717
    CrossrefPubMedGoogle Scholar
  • 5 Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60 (04) 640-646
    CrossrefPubMedGoogle Scholar
  • 6 Klawiter EC, Benzinger T, Roy A, Naismith RT, Parks BJ, Cross AH. Spinal cord ring enhancement in multiple sclerosis. Arch Neurol 2010; 67 (11) 1395-1398
    CrossrefPubMedGoogle Scholar
  • 7 Zalewski NL, Morris PP, Weinshenker BG. , et al. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2017; 88 (03) 218-225
    CrossrefPubMedGoogle Scholar
  • 8 Gajofatto A, Monaco S, Fiorini M. , et al. Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases. Arch Neurol 2010; 67 (06) 724-730
    PubMedGoogle Scholar
  • 9 Weinshenker BG, O'Brien PC, Petterson TM. , et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (06) 878-886
    CrossrefPubMedGoogle Scholar
  • 10 Keegan BM, Kaufmann TJ, Weinshenker BG. , et al. Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. Neurology 2016; 87 (16) 1713-1719
    CrossrefPubMedGoogle Scholar
  • 11 Lennon VA, Wingerchuk DM, Kryzer TJ. , et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106-2112
    CrossrefPubMedGoogle Scholar
  • 12 Flanagan EP, Cabre P, Weinshenker BG. , et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016; (e-pub ahead of print) DOI: 10.1002/ana.24617.
    CrossrefPubMedGoogle Scholar
  • 13 Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76 (18) 1589-1595
    CrossrefPubMedGoogle Scholar
  • 14 Wingerchuk DM, Banwell B, Bennett JL. , et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (02) 177-189
    CrossrefPubMedGoogle Scholar
  • 15 Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med 2010; 363 (06) 564-572
    CrossrefPubMedGoogle Scholar
  • 16 Flanagan EP, Kaufmann TJ, Krecke KN. , et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79 (03) 437-447
    CrossrefPubMedGoogle Scholar
  • 17 Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68 (08) 603-605
    CrossrefPubMedGoogle Scholar
  • 18 Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012; 69 (08) 1026-1031
    PubMedGoogle Scholar
  • 19 He Z, Ren M, Wang X, Guo Q, Qi X. Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2017; 13: 1-3
    CrossrefPubMedGoogle Scholar
  • 20 Flanagan EP, Weinshenker BG, Krecke KN. , et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72 (01) 81-87
    CrossrefPubMedGoogle Scholar
  • 21 Huh SY, Kim SH, Hyun JW. , et al. Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. Mult Scler 2017; 23 (03) 413-419
    CrossrefPubMedGoogle Scholar
  • 22 Yokote H, Nose Y, Ishibashi S. , et al. Spinal cord ring enhancement in patients with neuromyelitis optica. Acta Neurol Scand 2015; 132 (01) 37-41
    PubMedGoogle Scholar
  • 23 Kim HJ, Paul F, Lana-Peixoto MA. , et al; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84 (11) 1165-1173
    CrossrefPubMedGoogle Scholar
  • 24 Downer JJ, Leite MI, Carter R, Palace J, Küker W, Quaghebeur G. Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?. Neuroradiology 2012; 54 (04) 279-285
    CrossrefPubMedGoogle Scholar
  • 25 Tsivgoulis G, Kontokostas S, Boviatsis E, Bonakis A, Stefanis L, Voumvourakis K. Teaching neuroimages: neuromyelitis optica misdiagnosed as spinal cord tumor. Neurology 2014; 82 (04) e33
    CrossrefPubMedGoogle Scholar
  • 26 Hyun JW, Kim SH, Jeong IH, Lee SH, Kim HJ. Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder?. J Neurol Neurosurg Psychiatry 2015; 86 (11) 1280-1282
    CrossrefPubMedGoogle Scholar
  • 27 Krampla W, Aboul-Enein F, Jecel J. , et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 2009; 19 (10) 2535-2543
    CrossrefPubMedGoogle Scholar
  • 28 Asgari N, Flanagan EP, Fujihara K. , et al. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2017; 4 (04) e343
    CrossrefPubMedGoogle Scholar
  • 29 Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm 2016; 3 (03) e231
    CrossrefPubMedGoogle Scholar
  • 30 Fryer JP, Lennon VA, Pittock SJ. , et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014; 1 (01) e11
    CrossrefPubMedGoogle Scholar
  • 31 Pittock SJ, Lennon VA, Bakshi N. , et al. Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol 2014; 71 (11) 1433-1436
    CrossrefPubMedGoogle Scholar
  • 32 Pittock SJ, Lennon VA, de Seze J. , et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65 (01) 78-83
    PubMedGoogle Scholar
  • 33 Kleiter I, Gahlen A, Borisow N. , et al; Neuromyelitis Optica Study Group. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016; 79 (02) 206-216
    CrossrefPubMedGoogle Scholar
  • 34 Zalewski NL, Krecke KN, Weinshenker BG. , et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology 2016; 87 (07) 743-744
    CrossrefPubMedGoogle Scholar
  • 35 Flanagan EP, Hunt CH, Lowe V. , et al. [(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc 2013; 88 (11) 1204-1212
    CrossrefPubMedGoogle Scholar
  • 36 Huang JF, Aksamit AJ, Staff NP. MRI and PET imaging discordance in neurosarcoidosis. Neurology 2012; 79 (10) 1070
    CrossrefPubMedGoogle Scholar
  • 37 Gelfand JM, Bradshaw MJ, Stern BJ. , et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 2017; 89 (20) 2092-2100
    CrossrefPubMedGoogle Scholar
  • 38 Misu T, Sato DK, Nakashima I, Fujihara K. MOG-IgG serological status matters in paediatric ADEM. J Neurol Neurosurg Psychiatry 2015; 86 (03) 242
    CrossrefPubMedGoogle Scholar
  • 39 Hyun JW, Woodhall MR, Kim SH. , et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 2017; 88 (10) 811-817
    CrossrefPubMedGoogle Scholar
  • 40 Jarius S, Kleiter I, Ruprecht K. , et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation 2016; 13 (01) 281
    CrossrefPubMedGoogle Scholar
  • 41 Kitley J, Waters P, Woodhall M. , et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71 (03) 276-283
    CrossrefPubMedGoogle Scholar
  • 42 Young NP, Weinshenker BG, Parisi JE. , et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010; 133 (Pt 2): 333-348
    CrossrefPubMedGoogle Scholar
  • 43 Baumann M, Sahin K, Lechner C. , et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86 (03) 265-272
    CrossrefPubMedGoogle Scholar
  • 44 Krupp LB, Tardieu M, Amato MP. , et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
    CrossrefPubMedGoogle Scholar
  • 45 Pohl D, Alper G, Van Haren K. , et al. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology 2016; 87 (09) (Suppl. 02) S38-S45
    CrossrefPubMedGoogle Scholar
  • 46 Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341 (17) 1284-1291
    CrossrefPubMedGoogle Scholar
  • 47 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335 (8697): 1078-1080
    PubMedGoogle Scholar
  • 48 Uygunoglu U, Zeydan B, Ozguler Y. , et al. Myelopathy in Behçet's disease: the Bagel sign. Ann Neurol 2017; 82 (02) 288-298
    CrossrefPubMedGoogle Scholar
  • 49 Zeydan B, Uygunoglu U, Saip S. , et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm 2016; 3 (05) e258
    CrossrefPubMedGoogle Scholar
  • 50 Flanagan EP, McKeon A, Lennon VA. , et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011; 76 (24) 2089-2095
    CrossrefPubMedGoogle Scholar
  • 51 Pittock SJ, Lucchinetti CF, Parisi JE. , et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58 (01) 96-107
    CrossrefPubMedGoogle Scholar
  • 52 Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53 (05) 580-587
    CrossrefPubMedGoogle Scholar
  • 53 Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50 (03) 301-311
    CrossrefPubMedGoogle Scholar
  • 54 Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49 (02) 146-154
    CrossrefPubMedGoogle Scholar
  • 55 Sillevis Smitt P, Grefkens J, de Leeuw B. , et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249 (06) 745-753
    CrossrefPubMedGoogle Scholar
  • 56 Graus F, Keime-Guibert F, Reñe R. , et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124 (Pt 6): 1138-1148
    CrossrefPubMedGoogle Scholar
  • 57 Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47 (03) 297-305
    CrossrefPubMedGoogle Scholar
  • 58 Hoffmann LA, Jarius S, Pellkofer HL. , et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79 (07) 767-773
    CrossrefPubMedGoogle Scholar
  • 59 Guerra H, Pittock SJ, Moder KG, Froehling DA, Flanagan EP. Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. J Neurol Sci 2016; 361: 204-205
    CrossrefPubMedGoogle Scholar
  • 60 Hasegawa M, Yamashita J, Yamashima T, Ikeda K, Fujishima Y, Yamazaki M. Spinal cord infarction associated with primary antiphospholipid syndrome in a young child. Case report. J Neurosurg 1993; 79 (03) 446-450
    CrossrefPubMedGoogle Scholar
  • 61 Salvarani C, Brown Jr RD, Calamia KT. , et al. Primary CNS vasculitis with spinal cord involvement. Neurology 2008; 70 (24 Pt 2): 2394-2400
    CrossrefPubMedGoogle Scholar
  • 62 Rabinstein AA. Vascular myelopathies. Continuum (Minneap Minn) 2015; 21 (1 Spinal Cord Disorders): 67-83
    PubMedGoogle Scholar
  • 63 Flanagan EP, Hinson SR, Lennon VA. , et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 2017; 81 (02) 298-309
    CrossrefPubMedGoogle Scholar
  • 64 Zalewski NL, Tobin WO. CLIPPERS. Curr Neurol Neurosci Rep 2017; 17 (09) 65
    CrossrefPubMedGoogle Scholar
  • 65 Hwang BY, Liu A, Kern J, Goodwin CR, Wolinsky JP, Desai A. Epidural spinal involvement of Erdheim-Chester disease causing myelopathy. J Clin Neurosci 2015; 22 (09) 1532-1536
    CrossrefPubMedGoogle Scholar
  • 66 Takeuchi T, Sato M, Sonomura T, Itakura T. Erdheim-Chester disease associated with intramedullary spinal cord lesion. Br J Radiol 2012; 85 (1011): e62-e64
    CrossrefPubMedGoogle Scholar
  • 67 Carrasco-García de León S, Flores Barragán JM, Relea Calatayud F, Balcazar Rojas O. Extra-axial mass in the foramen magnum causing cervical compressive myelopathy as a complication of Rosai-Dorfman disease. J Clin Neurol 2017; 13 (03) 312-314
    CrossrefPubMedGoogle Scholar
  • 68 Sellner J, Hemmer B, Mühlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 2010; 34 (04) 371-379
    CrossrefPubMedGoogle Scholar
  • 69 Nakamura Y, Nakajima H, Tani H. , et al. Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report. BMC Neurol 2017; 17 (01) 76
    CrossrefPubMedGoogle Scholar
  • 70 Amano H, Miyamoto N, Shimura H. , et al. Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. BMC Neurol 2014; 14: 224
    CrossrefPubMedGoogle Scholar
  • 71 Jarius S, Ruprecht K, Kleiter I. , et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13 (01) 280
    CrossrefPubMedGoogle Scholar
  • 72 Ozawa H, Sato T, Hyodo H. , et al. Clinical significance of intramedullary Gd-DTPA enhancement in cervical myelopathy. Spinal Cord 2010; 48 (05) 415-422
    CrossrefPubMedGoogle Scholar
  • 73 Flanagan EP, Krecke KN, Marsh RW, Giannini C, Keegan BM, Weinshenker BG. Specific pattern of gadolinium enhancement in spondylotic myelopathy. Ann Neurol 2014; 76 (01) 54-65
    CrossrefPubMedGoogle Scholar
  • 74 Barreras P, Fitzgerald KC, Mealy MA. , et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology 2018; 90 (01) e12-e21
    CrossrefPubMedGoogle Scholar
  • 75 Amano Y, Machida T, Kumazaki T. Spinal cord infarcts with contrast enhancement of the cauda equina: two cases. Neuroradiology 1998; 40 (10) 669-672
    CrossrefPubMedGoogle Scholar
  • 76 Yuh WT, Marsh III EE, Wang AK. , et al. MR imaging of spinal cord and vertebral body infarction. AJNR Am J Neuroradiol 1992; 13 (01) 145-154
    PubMedGoogle Scholar
  • 77 Krings T, Geibprasert S. Spinal dural arteriovenous fistulas. AJNR Am J Neuroradiol 2009; 30 (04) 639-648
    CrossrefPubMedGoogle Scholar